Daniel Horber

Daniel Horber

Auto-generated profile, based on publicly available information

Daniel Horber

Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
UGUlrich Güller
Ulrich Güller
SHStefanie Hayoz
Stefanie Hayoz
DHDaniel Horber
Daniel Horber
WJWolfram Jochum
Wolfram Jochum
SDSara De Dosso
Sara De Dosso
Markus JoergerMarkus Joerger
Markus Joerger
Purpose: We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated colon cancer. Patients and Methods: This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with resected colon cancer stage II and III harboring an activating PIK3CA mutation were included. Because of financial constraints, the trial was prematurely closed. Randomization was 2:1 to aspirin 100 mg versus placebo daily for 3 years. The primary endpoint was disease-free survival (DFS). Secondary endpoints included the time to disease recurrence (TTR), overall survival, and adverse events. Results: Overall, 1,040 patients were screened for PIK3CA mutations, with 112 randomized to aspirin (N = 74) and placebo (N = 38). The median age was 66 years, and 42.9% were female. After a median follow-up of 4 years, 19 DFS events occurred, including 10 in the aspirin and nine in the placebo arm. The HR for DFS was 0.57 [90% confidence interval (CI), 0.27–1.22], in favor of aspirin (P = 0.11). DFS rates at 5 years were 86.5% (90% CI, 77.7%–92.0%) in the aspirin and 72.9% (90% CI, 55.7%–84.3%) in the placebo arm. The HR for TTR was 0.49 (90% CI, 0.21–1.19, P = 0.089) in favor of aspirin. No patient experienced aspirin-related serious adverse events. Conclusions: The SAKK 41/13 is the first randomized trial to provide clinical evidence of a protective effect of adjuvant aspirin in patients with resected PIK3CA-mutant colon cancer, with clinically relevant DFS and TTR improvements. Although results were not statistically significant because of premature study closure, adjuvant aspirin warrants individual consideration in patients with resected PIK3CA-mutant colon cancer stage II and III. See related commentary by Drew et al., p. 3107

1 August 2025
Verified
Other
Open access
UGUlrich Güller
Ulrich Güller
SHStefanie Hayoz
Stefanie Hayoz
DHDaniel Horber
Daniel Horber
WJWolfram Jochum
Wolfram Jochum
SDSara De Dosso
Sara De Dosso
Markus JoergerMarkus Joerger
Markus Joerger
Sensitivity analyses accounting for non-proportional hazards. Sensitivity analyses accounting for non-proportional hazards using restricted mean survival time. The separating curves over time indicate the benefit of aspirin over placebo on disease-free survival.

1 August 2025
Verified
Other
Open access
UGUlrich Güller
Ulrich Güller
SHStefanie Hayoz
Stefanie Hayoz
DHDaniel Horber
Daniel Horber
WJWolfram Jochum
Wolfram Jochum
SDSara De Dosso
Sara De Dosso
Markus JoergerMarkus Joerger
Markus Joerger
Recurrence-free rates including 90% confidence intervals at different time points

1 August 2025
Verified
Other
Open access
UGUlrich Güller
Ulrich Güller
SHStefanie Hayoz
Stefanie Hayoz
DHDaniel Horber
Daniel Horber
WJWolfram Jochum
Wolfram Jochum
SDSara De Dosso
Sara De Dosso
Markus JoergerMarkus Joerger
Markus Joerger
Overall survival. Kaplan-Meier curve of overall survival (including unstratified hazard ratio) – comparison between patients randomized to aspirin (in red) versus placebo (in blue).


1 August 2025
Verified
Other
Open access
UGUlrich Güller
Ulrich Güller
SHStefanie Hayoz
Stefanie Hayoz
DHDaniel Horber
Daniel Horber
WJWolfram Jochum
Wolfram Jochum
SDSara De Dosso
Sara De Dosso
Markus JoergerMarkus Joerger
Markus Joerger
Impact on disease-free survival by number of tablets taken per day in Cox regression analysis